caa a22 4500 605491054 CHVBK 20210128100508.0 cr unu---uuuuu 210128e20150601xx s 000 0 eng 10.1007/s10147-014-0731-1 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0731-1 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study [Elektronische Daten] [Naoto Takase, Koji Matsumoto, Takuma Onoe, Akihito Kitao, Maki Tanioka, Yoshitaka Kikukawa, Satoshi Yamaguchi, Kiyoshi Fujiwara, Shunichi Negoro] Background: Platinum agents are essential for treating gynecological malignancies, particularly ovarian cancer. However, multiple carboplatin doses may cause hypersensitivity reactions (HSRs). Carboplatin desensitization prevents life-threatening HSRs and promotes the successful completion of planned chemotherapy. Methods: Since January 2010, carboplatin desensitization was performed at our institution. Solutions with 1/1000, 1/100, and 1/10 dilutions of carboplatin and an undiluted solution were prepared in 250mL of 5% glucose. Each solution was administered as a 1-h intravenous infusion (4-step 4-h protocol). This retrospective analysis was approved by the institutional review board. Results: From January 2010 to December 2013, 20 patients with gynecological malignancies (median age 62years, range 43-74years) received desensitization treatment. The International Federation of Gynecology and Obstetrics stages at presentation were I, II, III, and IV in 1, 1, 15, 13 patients, respectively. During first-line and second-line treatments, 3 and 17 patients, respectively, experienced carboplatin-induced HSRs. The median carboplatin cycle number was 11 (range 2-16). In the first desensitization cycle, 17 (85%) patients completed treatment without adverse events, 2 experienced Grade 1 HSRs but completed treatment, and 1 experienced Grade 3 HSR and discontinued treatment. The first desensitization cycle completion rate was 95%. Of 83 desensitization cycles administered, 79 (95.2%) were completed. No treatment-related deaths occurred. Conclusions: Most patients completed the planned chemotherapy. Our protocol could be conducted safely with shorter duration and simpler procedures than previous protocols. Carboplatin desensitization seems beneficial for patients with a history of carboplatin-induced HSRs; however, the risk of HSR recurrence still remains. Desensitization should therefore be performed only by well-trained staff. Japan Society of Clinical Oncology, 2014 Ovarian cancer nationallicence Desensitization nationallicence Carboplatin nationallicence Hypersensitivity reaction nationallicence Gynecological malignancy nationallicence Takase Naoto Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut Matsumoto Koji Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut Onoe Takuma Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut Kitao Akihito Department of General Medicine, Public Toyooka Hospital, 1094 Tobera, 668-8501, Toyooka, Hyogo, Japan aut Tanioka Maki Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut Kikukawa Yoshitaka Department of Hematology, Kumamoto University School of Medicine, 860-8556, Kumamoto, Japan aut Yamaguchi Satoshi Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan aut Fujiwara Kiyoshi Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan aut Negoro Shunichi Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 566-573 1341-9625 20:3<566 2015 20 10147 https://doi.org/10.1007/s10147-014-0731-1 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0731-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Takase Naoto Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut NATIONALLICENCE 700 1- Matsumoto Koji Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut NATIONALLICENCE 700 1- Onoe Takuma Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut NATIONALLICENCE 700 1- Kitao Akihito Department of General Medicine, Public Toyooka Hospital, 1094 Tobera, 668-8501, Toyooka, Hyogo, Japan aut NATIONALLICENCE 700 1- Tanioka Maki Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut NATIONALLICENCE 700 1- Kikukawa Yoshitaka Department of Hematology, Kumamoto University School of Medicine, 860-8556, Kumamoto, Japan aut NATIONALLICENCE 700 1- Yamaguchi Satoshi Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan aut NATIONALLICENCE 700 1- Fujiwara Kiyoshi Department of Gynecology, Hyogo Cancer Center, 673-8558, Akashi, Hyogo, Japan aut NATIONALLICENCE 700 1- Negoro Shunichi Department of Medical Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, 673-8558, Akashi, Hyogo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/3(2015-06-01), 566-573 1341-9625 20:3<566 2015 20 10147